• 1
    Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. HEPATOLOGY 2002; 36: 479497.
  • 2
    Czaja AJ. Drug therapy in management of type 1 autoimmune hepatitis. Drugs 1999; 57: 4968.
  • 3
    Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820833.
  • 4
    Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 15101516.
    Direct Link:
  • 5
    Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951957.
  • 6
    Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848857.
  • 7
    Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. HEPATOLOGY 2005; 42: 5362.
  • 8
    Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, Makino Y, et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 11971205.
  • 9
    Czaja A, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver 2003; 23: 116.
  • 10
    Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1–B8-DR3 are independent risk factors. HEPATOLOGY 1991; 13: 701706.
  • 11
    Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 20282203.
  • 12
    Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. HEPATOLOGY 1997; 25: 317323.
  • 13
    Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. HEPATOLOGY 1992; 15: 215221.
  • 14
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 15021507.
  • 15
    Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713717.
  • 16
    Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929938.
  • 17
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 18
    Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 12901295.
  • 19
    Ward M, Lazda VA, Gaddis PJ, Stormoen BM, Smith Y, Fabrega AJ, et al. In vitro response to immunosuppressive agents in blacks. Transplant Proc 1993; 25: 24702471.
  • 20
    Devlin JJ, O'Grady JG, Tan KC, Calne RY, Williams R. Ethnic variations in patient and graft survival after liver transplantation. Identification of a new risk factor for chronic allograft rejection. Transplantation 1993; 56: 13811384.
  • 21
    Neylan JF, for the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515523.
  • 22
    Fitzsimmons WE, Bekersky I, Dressler D, Raye K, Hodosh E, Mekki Q. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998; 30: 13591364.
  • 23
    Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 1995; 9: 379394.
  • 24
    McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994; 55: 1520.
  • 25
    Chocair PR, Duley JA, Sabbaga E, Arap S, Simmonds HA, Cameron JS. Fast and slow methylators: do racial differences influence risk of allograft rejection? Q J Med 1993; 86: 359363.
  • 26
    Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001; 96: 33903394.
    Direct Link:
  • 27
    Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 12221227.
  • 28
    Petri M. The effect of race on incidence and clinical course in systemic lupus erythematosus: the Hopkins lupus cohort. J Am Med Womens Assoc 1998; 53: 912.
  • 29
    Tull ES, Barinas E. A two fold excess mortality among black compared with white IDDM patients in Allegheny county, Pennsylvania. Pittsburgh DERI Mortality Study Group. Diabetes Care 1996; 19: 13441347.
  • 30
    Autoimmune hepatitis is a more common indication for orthotopic liver transplantation among African American patients than among non-African American patients. Transplantation 2006; 82(suppl 2): 981.
  • 31
    D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005; 25: 325330.
  • 32
    Verma S, Redeker A. In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow up associated with a poorer outcome? HEPATOLOGY 2005; 42: 1237.